[
    "{\"step_by_step_thinking\": \"This study is assessing the antileukemic activity of a new tyrosine kinase inhibitor in patients with chronic myeloid leukemia in blast crisis. All patients are informed that they would be treated with the tyrosine kinase inhibitor, indicating that the treatment is not blinded. The patients are assigned to successive dose cohorts, indicating that there is no randomization. Therefore, this study can be best described as an open-labeled clinical trial.\", \"answer_choice\": \"C\"}"
]